Isolated diastolic hypertension and target organ damage: Findings from the STANISLAS cohort.


Journal

Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272

Informations de publication

Date de publication:
Nov 2021
Historique:
revised: 02 08 2021
received: 18 06 2021
accepted: 05 08 2021
pubmed: 16 9 2021
medline: 10 11 2021
entrez: 15 9 2021
Statut: ppublish

Résumé

Isolated diastolic hypertension (IDH) is defined as diastolic blood pressure (DBP) ≥80 mmHg and systolic blood pressure (SBP) <130 mmHg according to 2017 ACC/AHA guidelines. The effective cardiovascular risk linked to IDH is debated. IDH might contribute marginally to hypertension-related target organ damage (TOD) development. In this cross-sectional analysis 1605 subjects from the STANISLAS cohort, a large familiar longitudinal study from Eastern France, were included. Participants were categorized according to average values at 24-h ABP recording as having normal BP (SBP < 130/DBP < 80 mmHg); combined hypertension (SBP ≥130/DBP ≥80 mmHg or on antihypertensive treatment); IDH (SBP <130/DBP >80 mmHg); isolated systolic hypertension (ISH: SBP ≥130/DBP <80 mmHg). The association between hypertension status and TOD was assessed by multivariable-adjusted logistic models. Using normotension as reference, IDH was not significantly associated with NTproBNP levels (adjusted odds ratio [OR] 1.04 [95%CI 0.82;1.32], p = .750), microalbuminuria (OR 0.99 [0.69; 1.42], p = .960), diastolic dysfunction (OR 1.53 [0.88; 2.68], p = .130), left ventricular (LV) mass index (OR per 10 g/m IDH was not significantly associated with TOD. Further studies are needed to clarify the clinical role of IDH. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01391442.

Sections du résumé

BACKGROUND BACKGROUND
Isolated diastolic hypertension (IDH) is defined as diastolic blood pressure (DBP) ≥80 mmHg and systolic blood pressure (SBP) <130 mmHg according to 2017 ACC/AHA guidelines. The effective cardiovascular risk linked to IDH is debated.
HYPOTHESIS OBJECTIVE
IDH might contribute marginally to hypertension-related target organ damage (TOD) development.
METHODS METHODS
In this cross-sectional analysis 1605 subjects from the STANISLAS cohort, a large familiar longitudinal study from Eastern France, were included. Participants were categorized according to average values at 24-h ABP recording as having normal BP (SBP < 130/DBP < 80 mmHg); combined hypertension (SBP ≥130/DBP ≥80 mmHg or on antihypertensive treatment); IDH (SBP <130/DBP >80 mmHg); isolated systolic hypertension (ISH: SBP ≥130/DBP <80 mmHg). The association between hypertension status and TOD was assessed by multivariable-adjusted logistic models.
RESULTS RESULTS
Using normotension as reference, IDH was not significantly associated with NTproBNP levels (adjusted odds ratio [OR] 1.04 [95%CI 0.82;1.32], p = .750), microalbuminuria (OR 0.99 [0.69; 1.42], p = .960), diastolic dysfunction (OR 1.53 [0.88; 2.68], p = .130), left ventricular (LV) mass index (OR per 10 g/m
CONCLUSIONS CONCLUSIONS
IDH was not significantly associated with TOD. Further studies are needed to clarify the clinical role of IDH. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01391442.

Identifiants

pubmed: 34523741
doi: 10.1002/clc.23713
pmc: PMC8571544
doi:

Banques de données

ClinicalTrials.gov
['NCT01391442']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1516-1525

Subventions

Organisme : Fondation de Recherche en Hypertension Artérielle
Organisme : ERA-CVD EXPERT
ID : ANR-16-ECVD-0002-02
Organisme : FOCUS-MR
ID : ANR-15-CE14-0032-01
Organisme : CPER IT2MP
Organisme : FEDER Lorraine
Organisme : French PIA project
ID : ANR-15-IDEX-04-LUE
Organisme : FIGHT-HF
ID : ANR-15-RHU-0004
Organisme : French National Research Agency
Organisme : Contrat de Plan Etat-Lorraine and FEDER Lorraine
Organisme : French Ministry of Health

Informations de copyright

© 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.

Références

Stroke. 1995 Jan;26(1):25-9
pubmed: 7839392
J Hypertens. 2014 Mar;32(3):518-24
pubmed: 24477096
Clin Cardiol. 2021 Nov;44(11):1516-1525
pubmed: 34523741
Hypertension. 2011 Apr;57(4):702-9
pubmed: 21383312
J Am Coll Cardiol. 2018 May 15;71(19):2199-2269
pubmed: 29146533
J Am Coll Cardiol. 2015 Dec 1;66(21):2472
pubmed: 26610882
PLoS One. 2015 Apr 08;10(4):e0122336
pubmed: 25853818
Hypertension. 2000 Nov;36(5):894-900
pubmed: 11082163
Circulation. 2014 Aug 5;130(6):466-74
pubmed: 24906822
Circulation. 2012 Dec 11;126(24):2890-909
pubmed: 23159553
J Card Fail. 2008 Oct;14(8):687-94
pubmed: 18926441
Int J Cardiol. 1995 Mar 3;48(3):311-6
pubmed: 7782147
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Chin Med J (Engl). 2011 Nov;124(22):3676-81
pubmed: 22340223
Hypertension. 2001 Mar;37(3):869-74
pubmed: 11244010
Hypertension. 1995 Sep;26(3):377-82
pubmed: 7649569
J Am Heart Assoc. 2016 Jun 16;5(6):
pubmed: 27312804
Int J Cardiol. 2017 Jul 1;238:140-143
pubmed: 28343761
J Hum Hypertens. 2002 Jan;16(1):61-6
pubmed: 11840231
J Am Soc Echocardiogr. 2019 Jul;32(7):854-865.e8
pubmed: 31104890
J Hypertens. 2012 Mar;30(3):445-8
pubmed: 22278144
J Hypertens. 2002 Mar;20(3):399-404
pubmed: 11875306
J Am Coll Cardiol. 2017 Jun 27;69(25):3119-3121
pubmed: 28641802
JAMA. 2020 Jan 28;323(4):329-338
pubmed: 31990314
Acta Cardiol. 1999 Oct;54(5):277-82
pubmed: 10596307
J Hypertens. 2009 Oct;27(10):2036-43
pubmed: 19587608
Int J Epidemiol. 2018 Apr 1;47(2):395-395j
pubmed: 29220499
J Hypertens. 2017 Sep;35(9):1727-1741
pubmed: 28767484
Arch Intern Med. 2000 Nov 27;160(21):3301-6
pubmed: 11088093
Circulation. 2020 Jun 2;141(22):1778-1786
pubmed: 32479205
Eur J Echocardiogr. 2009 Mar;10(2):165-93
pubmed: 19270053
Am J Hypertens. 1997 Jun;10(6):634-9
pubmed: 9194509
Am J Hypertens. 2010 Apr;23(4):405-12
pubmed: 20044741
Circulation. 1993 Oct;88(4 Pt 1):1444-55
pubmed: 8403291
Prog Cardiovasc Dis. 1986 Nov-Dec;29(3 Suppl 1):99-118
pubmed: 3538183
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Am Heart J. 1988 Oct;116(4):1124-33
pubmed: 2972182
J Hypertens. 2012 Jul;30(7):1289-99
pubmed: 22499289
Am J Cardiol. 2000 Jan 15;85(2):251-5
pubmed: 10955386
Vasc Med. 2011 Aug;16(4):239-46
pubmed: 21730007
Eur Heart J. 2006 Nov;27(21):2588-605
pubmed: 17000623
Lancet. 2008 May 3;371(9623):1513-8
pubmed: 18456100
J Hypertens. 2013 Sep;31(9):1731-68
pubmed: 24029863
J Hypertens. 1995 Aug;13(8):823-9
pubmed: 8557959

Auteurs

Luca Monzo (L)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University, Rome, Italy.

João Pedro Ferreira (JP)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Zohra Lamiral (Z)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Erwan Bozec (E)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Jean-Marc Boivin (JM)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Olivier Huttin (O)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Marilucy Lopez-Sublet (M)

Department of Internal Medicine, ESH Hypertension Excellence Centre, CHU Avicenne, AP-HP, F-CRIN INI-CRCT, Nancy, France.

Nicolas Girerd (N)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Faiez Zannad (F)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Patrick Rossignol (P)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH